Krebs Biochemicals & Industries Ltd EPS
Krebs Biochemicals & Industries Ltd
NSE: KREBSBIO
EPS
Key Highlights
- The Earning per Share of Krebs Biochemicals & Industries Ltd is ₹ -10.6 as of 27 Mar 26 The earning per share of Krebs Biochemicals & Industries Ltd changed from ₹ -2.4 to ₹ -1.45 over 7 quarters. This represents a CAGR of -25.02% .
Historical Earning per Share of Krebs Biochemicals & Industries Ltd
EPS, or Earnings Per Share, is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It indicates a company's profitability and is calculated by dividing net income by the number of outstanding shares.
Historical Earning per Share of Krebs Biochemicals & Industries Ltd
Company Fundamentals for Krebs Biochemicals & Industries Ltd
Market Cap
94 Cr
EPS
0.0
P/E Ratio (TTM)
0.0
P/B Ratio (TTM)
0.0
Day’s High
47.0
Day’s Low
43.25
DTE
-1.4
ROE
14.2
52 Week High
113.9
52 Week Low
43.25
ROCE
-14.9
Market Price of Krebs Biochemicals & Industries Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
| Date | |
|---|---|
| 27 Mar 2026 | 43.63 |
| 25 Mar 2026 | 47.13 |
| 24 Mar 2026 | 47.31 |
| 23 Mar 2026 | 47.03 |
| 20 Mar 2026 | 47.96 |
| 19 Mar 2026 | 49.19 |
| 18 Mar 2026 | 49.12 |
| 17 Mar 2026 | 48.59 |
| 16 Mar 2026 | 50.21 |
| 13 Mar 2026 | 53.5 |
SWOT Analysis Of Krebs Biochemicals & Industries Ltd
BlinkX Score for Krebs Biochemicals & Industries Ltd
Asset Value vs Market Value of Krebs Biochemicals & Industries Ltd
Market Value
₹ 94
Asset Value
Value addition
8.2 X
₹ 10
* All values are in ₹ crores
Competitive Comparison of EPS
| Company | Market Cap | EPS |
|---|
Krebs Biochemicals & Industries Ltd | 94.07 | - |
Sun Pharmaceutical Industries Ltd | 430837 | 50.61 |
Divis Laboratories Ltd | 159175 | 95.43 |
Torrent Pharmaceuticals Ltd | 144394 | 68.12 |
Dr Reddys Laboratories Ltd | 106999 | 66.71 |
Lupin Ltd | 106749 | 108.84 |
| Company | |
|---|---|
| Krebs Biochemicals & Industries Ltd | 94.07 |
| Sun Pharmaceutical Industries Ltd | 430837 |
| Divis Laboratories Ltd | 159175 |
| Torrent Pharmaceuticals Ltd | 144394 |
| Dr Reddys Laboratories Ltd | 106999 |
| Lupin Ltd | 106749 |
Historical Market Cap of Krebs Biochemicals & Industries Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Krebs Biochemicals & Industries Ltd
Historical Revenue of Krebs Biochemicals & Industries Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Krebs Biochemicals & Industries Ltd
Historical EBITDA of Krebs Biochemicals & Industries Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Krebs Biochemicals & Industries Ltd
Historical Net Profit of Krebs Biochemicals & Industries Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Krebs Biochemicals & Industries Ltd
Dividend Payout Over Time
Krebs Biochemicals & Industries Ltd News Hub
Krebs Biochemicals & Industries reports standalone net loss of Rs 5.17 crore in the June 2024 quarter
Net Loss of Krebs Biochemicals & Industries reported to Rs 5.17 crore in the quarter ended June 2024
Read more
07 Aug 24
Krebs Biochemicals & Industries schedules AGM
Krebs Biochemicals & Industries announced that the 32th Annual General Meeting (AGM) of the company
Read more
09 Sept 24
Krebs Biochemicals & Industries to conduct board meeting
Krebs Biochemicals & Industries will hold a meeting of the Board of Directors of the Company on 11 N
Read more
29 Oct 24
Krebs Biochemicals & Industries reports standalone net loss of Rs 5.76 crore in the September 2024 quarter
Net Loss of Krebs Biochemicals & Industries reported to Rs 5.76 crore in the quarter ended September
Read more
11 Nov 24
